Selected research
Market Structure
Global AI Pharma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global AI Pharma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of AI Pharma include Recursion, Insilico Medicine, Exscientia, BenevolentAI, Atomwise, Roivant Sciences, Schrödinger, Lantern Pharma and XtalPi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global AI Pharma market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of AI Pharma and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents AI Pharma revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the AI Pharma market size, projected growth trends, production technologies, key applications, and end-use industries.
AI Pharma Segment by Company
Recursion
Insilico Medicine
Exscientia
BenevolentAI
Atomwise
Roivant Sciences
Schrödinger
Lantern Pharma
XtalPi
Landos Biopharma
Relay Therapeutics
Accutar Biotech
Deep Genomics
Oncocross
AI Therapeutics
BioMap
METiS Pharmaceuticals
NeoX Biotech
StoneWise
Deep Intelligent Pharma
Gigaceuticals
Chemical.AI
Artivila
Galixir
Xbiome
AI Pharma Segment by Type
Self-developed Oipeline
Contract Research Organization (CRO)
Other
AI Pharma Segment by Application
Preclinical Stage (Optimization of Lead Compounds, etc.)
Clinical Trial Phase (Predicting Treatment Outcome, etc.)
AI Pharma Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Pharma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of AI Pharma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Pharma industry.
Chapter 3: Detailed analysis of AI Pharma companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI Pharmarevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Self-developed Oipeline
- Contract Research Organization (CRO)
- Other
Applications
- Preclinical Stage (Optimization of Lead Compounds, etc.)
- Clinical Trial Phase (Predicting Treatment Outcome, etc.)
Companies covered
- Recursion
- Insilico Medicine
- Exscientia
- BenevolentAI
- Atomwise
- Roivant Sciences
- Schrödinger
- Lantern Pharma
- XtalPi
- Landos Biopharma
- Relay Therapeutics
- Accutar Biotech
- Deep Genomics
- Oncocross
- AI Therapeutics
- BioMap
- METiS Pharmaceuticals
- NeoX Biotech
- StoneWise
- Deep Intelligent Pharma
- Gigaceuticals
- Chemical.AI
- Artivila
- Galixir
- Xbiome
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global AI Pharma Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Self-developed Oipeline
- 1.2.3 Contract Research Organization (CRO)
- 1.2.4 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global AI Pharma Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Preclinical Stage (Optimization of Lead Compounds, etc.)
- 1.3.3 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
- 1.4 Global Market Growth Prospects
- 1.5 Global AI Pharma Growth Trends by Region
- 1.5.1 Global AI Pharma Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 AI Pharma Market Size by Region (2021-2026)
- 1.5.3 AI Pharma Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global AI Pharma Market Dynamics
- 2.1 AI Pharma Industry Trends
- 2.2 AI Pharma Industry Drivers
- 2.3 AI Pharma Industry Opportunities and Challenges
- 2.4 AI Pharma Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global AI Pharma Revenue by Company (2021-2026)
- 3.2 Global AI Pharma Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global AI Pharma Key Company Head office and Area Served
- 3.4 Global AI Pharma Company, Product Type & Application
- 3.5 Global AI Pharma Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global AI Pharma Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 AI Pharma Players Market Share by Revenue in 2025
- 3.6.3 2025 AI Pharma Tier 1, Tier 2, and Tier 3
4 AI Pharma Market by Type
- 4.1 Global AI Pharma Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global AI Pharma Market Size by Type (2021-2032)
- 4.3 Global AI Pharma Market Size Share by Type (2021-2032)
5 AI Pharma Market by Application
- 5.1 Global AI Pharma Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global AI Pharma Market Size by Application (2021-2032)
- 5.3 Global AI Pharma Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Recursion
- 6.1.1 Recursion Company Information
- 6.1.2 Recursion Business Overview
- 6.1.3 Recursion AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Recursion AI Pharma Product Portfolio
- 6.1.5 Recursion Recent Developments
- 6.2 Insilico Medicine
- 6.2.1 Insilico Medicine Company Information
- 6.2.2 Insilico Medicine Business Overview
- 6.2.3 Insilico Medicine AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Insilico Medicine AI Pharma Product Portfolio
- 6.2.5 Insilico Medicine Recent Developments
- 6.3 Exscientia
- 6.3.1 Exscientia Company Information
- 6.3.2 Exscientia Business Overview
- 6.3.3 Exscientia AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Exscientia AI Pharma Product Portfolio
- 6.3.5 Exscientia Recent Developments
- 6.4 BenevolentAI
- 6.4.1 BenevolentAI Company Information
- 6.4.2 BenevolentAI Business Overview
- 6.4.3 BenevolentAI AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 BenevolentAI AI Pharma Product Portfolio
- 6.4.5 BenevolentAI Recent Developments
- 6.5 Atomwise
- 6.5.1 Atomwise Company Information
- 6.5.2 Atomwise Business Overview
- 6.5.3 Atomwise AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Atomwise AI Pharma Product Portfolio
- 6.5.5 Atomwise Recent Developments
- 6.6 Roivant Sciences
- 6.6.1 Roivant Sciences Company Information
- 6.6.2 Roivant Sciences Business Overview
- 6.6.3 Roivant Sciences AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Roivant Sciences AI Pharma Product Portfolio
- 6.6.5 Roivant Sciences Recent Developments
- 6.7 Schrödinger
- 6.7.1 Schrödinger Company Information
- 6.7.2 Schrödinger Business Overview
- 6.7.3 Schrödinger AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Schrödinger AI Pharma Product Portfolio
- 6.7.5 Schrödinger Recent Developments
- 6.8 Lantern Pharma
- 6.8.1 Lantern Pharma Company Information
- 6.8.2 Lantern Pharma Business Overview
- 6.8.3 Lantern Pharma AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Lantern Pharma AI Pharma Product Portfolio
- 6.8.5 Lantern Pharma Recent Developments
- 6.9 XtalPi
- 6.9.1 XtalPi Company Information
- 6.9.2 XtalPi Business Overview
- 6.9.3 XtalPi AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 XtalPi AI Pharma Product Portfolio
- 6.9.5 XtalPi Recent Developments
- 6.10 Landos Biopharma
- 6.10.1 Landos Biopharma Company Information
- 6.10.2 Landos Biopharma Business Overview
- 6.10.3 Landos Biopharma AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Landos Biopharma AI Pharma Product Portfolio
- 6.10.5 Landos Biopharma Recent Developments
- 6.11 Relay Therapeutics
- 6.11.1 Relay Therapeutics Company Information
- 6.11.2 Relay Therapeutics Business Overview
- 6.11.3 Relay Therapeutics AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Relay Therapeutics AI Pharma Product Portfolio
- 6.11.5 Relay Therapeutics Recent Developments
- 6.12 Accutar Biotech
- 6.12.1 Accutar Biotech Company Information
- 6.12.2 Accutar Biotech Business Overview
- 6.12.3 Accutar Biotech AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Accutar Biotech AI Pharma Product Portfolio
- 6.12.5 Accutar Biotech Recent Developments
- 6.13 Deep Genomics
- 6.13.1 Deep Genomics Company Information
- 6.13.2 Deep Genomics Business Overview
- 6.13.3 Deep Genomics AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Deep Genomics AI Pharma Product Portfolio
- 6.13.5 Deep Genomics Recent Developments
- 6.14 Oncocross
- 6.14.1 Oncocross Company Information
- 6.14.2 Oncocross Business Overview
- 6.14.3 Oncocross AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Oncocross AI Pharma Product Portfolio
- 6.14.5 Oncocross Recent Developments
- 6.15 AI Therapeutics
- 6.15.1 AI Therapeutics Company Information
- 6.15.2 AI Therapeutics Business Overview
- 6.15.3 AI Therapeutics AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 AI Therapeutics AI Pharma Product Portfolio
- 6.15.5 AI Therapeutics Recent Developments
- 6.16 BioMap
- 6.16.1 BioMap Company Information
- 6.16.2 BioMap Business Overview
- 6.16.3 BioMap AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 BioMap AI Pharma Product Portfolio
- 6.16.5 BioMap Recent Developments
- 6.17 METiS Pharmaceuticals
- 6.17.1 METiS Pharmaceuticals Company Information
- 6.17.2 METiS Pharmaceuticals Business Overview
- 6.17.3 METiS Pharmaceuticals AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 METiS Pharmaceuticals AI Pharma Product Portfolio
- 6.17.5 METiS Pharmaceuticals Recent Developments
- 6.18 NeoX Biotech
- 6.18.1 NeoX Biotech Company Information
- 6.18.2 NeoX Biotech Business Overview
- 6.18.3 NeoX Biotech AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 NeoX Biotech AI Pharma Product Portfolio
- 6.18.5 NeoX Biotech Recent Developments
- 6.19 StoneWise
- 6.19.1 StoneWise Company Information
- 6.19.2 StoneWise Business Overview
- 6.19.3 StoneWise AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 StoneWise AI Pharma Product Portfolio
- 6.19.5 StoneWise Recent Developments
- 6.20 Deep Intelligent Pharma
- 6.20.1 Deep Intelligent Pharma Company Information
- 6.20.2 Deep Intelligent Pharma Business Overview
- 6.20.3 Deep Intelligent Pharma AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Deep Intelligent Pharma AI Pharma Product Portfolio
- 6.20.5 Deep Intelligent Pharma Recent Developments
- 6.21 Gigaceuticals
- 6.21.1 Gigaceuticals Company Information
- 6.21.2 Gigaceuticals Business Overview
- 6.21.3 Gigaceuticals AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.21.4 Gigaceuticals AI Pharma Product Portfolio
- 6.21.5 Gigaceuticals Recent Developments
- 6.22 Chemical.AI
- 6.22.1 Chemical.AI Company Information
- 6.22.2 Chemical.AI Business Overview
- 6.22.3 Chemical.AI AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.22.4 Chemical.AI AI Pharma Product Portfolio
- 6.22.5 Chemical.AI Recent Developments
- 6.23 Artivila
- 6.23.1 Artivila Company Information
- 6.23.2 Artivila Business Overview
- 6.23.3 Artivila AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.23.4 Artivila AI Pharma Product Portfolio
- 6.23.5 Artivila Recent Developments
- 6.24 Galixir
- 6.24.1 Galixir Company Information
- 6.24.2 Galixir Business Overview
- 6.24.3 Galixir AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.24.4 Galixir AI Pharma Product Portfolio
- 6.24.5 Galixir Recent Developments
- 6.25 Xbiome
- 6.25.1 Xbiome Company Information
- 6.25.2 Xbiome Business Overview
- 6.25.3 Xbiome AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.25.4 Xbiome AI Pharma Product Portfolio
- 6.25.5 Xbiome Recent Developments
7 North America
- 7.1 North America AI Pharma Market Size (2021-2032)
- 7.2 North America AI Pharma Market Size by Type
- 7.2.1 North America AI Pharma Market Size by Type (2021-2026)
- 7.2.2 North America AI Pharma Market Size by Type (2027-2032)
- 7.2.3 North America AI Pharma Market Share by Type (2021-2032)
- 7.3 North America AI Pharma Market Size by Application
- 7.3.1 North America AI Pharma Market Size by Application (2021-2026)
- 7.3.2 North America AI Pharma Market Size by Application (2027-2032)
- 7.3.3 North America AI Pharma Market Share by Application (2021-2032)
- 7.4 North America AI Pharma Market Size by Country
- 7.4.1 North America AI Pharma Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America AI Pharma Market Size by Country (2021-2026)
- 7.4.3 North America AI Pharma Market Size by Country (2027-2032)
- 7.4.4 North America AI Pharma Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe AI Pharma Market Size (2021-2032)
- 8.2 Europe AI Pharma Market Size by Type
- 8.2.1 Europe AI Pharma Market Size by Type (2021-2026)
- 8.2.2 Europe AI Pharma Market Size by Type (2027-2032)
- 8.2.3 Europe AI Pharma Market Share by Type (2021-2032)
- 8.3 Europe AI Pharma Market Size by Application
- 8.3.1 Europe AI Pharma Market Size by Application (2021-2026)
- 8.3.2 Europe AI Pharma Market Size by Application (2027-2032)
- 8.3.3 Europe AI Pharma Market Share by Application (2021-2032)
- 8.4 Europe AI Pharma Market Size by Country
- 8.4.1 Europe AI Pharma Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe AI Pharma Market Size by Country (2021-2026)
- 8.4.3 Europe AI Pharma Market Size by Country (2027-2032)
- 8.4.4 Europe AI Pharma Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China AI Pharma Market Size (2021-2032)
- 9.2 China AI Pharma Market Size by Type
- 9.2.1 China AI Pharma Market Size by Type (2021-2026)
- 9.2.2 China AI Pharma Market Size by Type (2027-2032)
- 9.2.3 China AI Pharma Market Share by Type (2021-2032)
- 9.3 China AI Pharma Market Size by Application
- 9.3.1 China AI Pharma Market Size by Application (2021-2026)
- 9.3.2 China AI Pharma Market Size by Application (2027-2032)
- 9.3.3 China AI Pharma Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia AI Pharma Market Size (2021-2032)
- 10.2 Asia AI Pharma Market Size by Type
- 10.2.1 Asia AI Pharma Market Size by Type (2021-2026)
- 10.2.2 Asia AI Pharma Market Size by Type (2027-2032)
- 10.2.3 Asia AI Pharma Market Share by Type (2021-2032)
- 10.3 Asia AI Pharma Market Size by Application
- 10.3.1 Asia AI Pharma Market Size by Application (2021-2026)
- 10.3.2 Asia AI Pharma Market Size by Application (2027-2032)
- 10.3.3 Asia AI Pharma Market Share by Application (2021-2032)
- 10.4 Asia AI Pharma Market Size by Country
- 10.4.1 Asia AI Pharma Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia AI Pharma Market Size by Country (2021-2026)
- 10.4.3 Asia AI Pharma Market Size by Country (2027-2032)
- 10.4.4 Asia AI Pharma Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa AI Pharma Market Size (2021-2032)
- 11.2 South America, Middle East & Africa AI Pharma Market Size by Type
- 11.2.1 South America, Middle East & Africa AI Pharma Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa AI Pharma Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa AI Pharma Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa AI Pharma Market Size by Application
- 11.3.1 South America, Middle East & Africa AI Pharma Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa AI Pharma Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa AI Pharma Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa AI Pharma Market Size by Country
- 11.4.1 South America, Middle East & Africa AI Pharma Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa AI Pharma Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa AI Pharma Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa AI Pharma Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst